Overall rank by patents
#28,871
Across all tracked assignees
USPTO 2015–2025 USPTO PatentsView US Corporation
Genecentric Therapeutics, Inc.
USPTO PatentsView assignee record - 9 granted patents across 6 technology areas, active 2020–2025. Filing-trend and competitive-moat analysis cross-referenced to USPTO Patent Public Search. Primary class: C12Q (MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS ; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICR).
9
Total patents granted
6
CPC technology areas
10.4
Avg claims per patent
-
5-year filing velocity
The verdict
Genecentric holds 9 US patents across 6 technology areas, rank #28,871 of 50,000 tracked assignees.
- #28,871
- of 50,000 US assignees by volume
- Top 54%
- by Innovation Score (34.0/100)
- 10.4
- avg claims per patent
Portfolio overview
Genecentric Therapeutics, Inc. has been granted 9 US utility patents between 2020 and 2025, placing Genecentric Therapeutics, Inc. at rank #28,871 across all assignees tracked by PlainPatent. This portfolio spans 6 distinct Cooperative Patent Classification (CPC) subclasses, averaging 10.4 claims per patent with primary concentration in C12Q (MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS ; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICR). As a US Corporation, Genecentric Therapeutics, Inc. is one of the more focused assignees in the PatentsView dataset. By volume, Genecentric sits between Gatekeeper Ltd. (9 patents, rank #28,867) and Genesis Systems Llc (9 patents, rank #28,875) - the closest US assignees by grant volume. The composite Innovation Score of 34.0/100 blends portfolio volume, filing velocity, technology breadth, and claim depth into a single comparable measure drawn directly from USPTO PatentsView records.
Filing cadence tells the strategic story. Historical data spans 2020 through 2025, with 9 total grants over that period. Velocity comparisons require five years of historical filings to calibrate. The US Corporation classification further shapes interpretation, since corporate, government, and individual filers pursue patents for materially different reasons.
Claim depth and technology breadth together indicate competitive posture. Genecentric Therapeutics, Inc.'s 10.4 average claims per patent suggests focused, narrowly drawn claims typical of single-invention filings, while concentration in 6 subclasses points to a focused technical program. Combined with portfolio volume, these signals let analysts, investors, and licensing professionals benchmark Genecentric Therapeutics, Inc. against peers pursuing similar technology classes.
Who files at Genecentric's volume?
Granted US patents 2015–2025 versus its nearest-ranked assignees by volume, this company marked ◀
- Gatekeeper
Gatekeeper Ltd.
9 patents
- Geckobrands
Geckobrands, LLC
9 patents
- Geerpres
Geerpres, Inc.
9 patents
- Gems Sensors
Gems Sensors Inc.
9 patents
- Genelux
Genelux Corporation
9 patents
- General Lasertron…
General Lasertronics Corporation
9 patents
- Generon (Shanghai)
Generon (Shanghai) Corporation Ltd.
9 patents
- Genesis Systems
Genesis Systems LLC
9 patents
- Genecentric Thera… ◀
GeneCentric Therapeutics, Inc.
9 patents
What this shows Genecentric holds 9 patents at rank #28,871, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.
Companies ranked near Genecentric
By rank, the assignees closest to #28,871 in granted patent volume.
- Gatekeeper Ltd. #28,867 · 9 patents
- Geckobrands, Llc #28,868 · 9 patents
- Geerpres, Inc. #28,869 · 9 patents
- Gems Sensors Inc. #28,870 · 9 patents
- Genelux Corporation #28,872 · 9 patents
- General Lasertronics Corporation #28,873 · 9 patents
- Generon (shanghai) Corporation Ltd. #28,874 · 9 patents
- Genesis Systems Llc #28,875 · 9 patents
Leaders in C12Q (Measuring OR Testing Processes Involving Enzymes)
Other assignees with the most granted patents in Genecentric's primary technology class.
- The Regents Of The University Of California 581 in class
- Life Technologies Corporation 546 in class
- Illumina, Inc. 445 in class
- President And Fellows Of Harvard College 387 in class
- Immatics Biotechnologies Gmbh 286 in class
- 10x Genomics, Inc. 282 in class
- The Board Of Trustees Of The Leland Stanford Junior University 266 in class
- Pacific Biosciences OF California, Inc. 259 in class
Genecentric's Innovation Score vs. every tracked assignee
Composite of portfolio volume, filing velocity, technology breadth, and claim depth (0–100)
34 Top 54% higher than 46% of 50,000 US assignees
Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.
Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025
Grants by year
Teal-shaded recent years (2020–present) versus the 2020–2019 baseline. Full figures in the table below.
View data table
| Year | Patents Granted | Share of Period |
|---|---|---|
| 2020 | 1 | 11.1% |
| 2021 | 2 | 22.2% |
| 2023 | 2 | 22.2% |
| 2024 | 3 | 33.3% |
| 2025 | 1 | 11.1% |
Which technologies does Genecentric Therapeutics, Inc. patent most?
Top 6 of 6 technology areas
Patent Moat Analysis
Portfolio Volume Light
Tech Breadth Focused
Claim Depth Simple
Frequently Asked Questions
How many patents does Genecentric Therapeutics, Inc. hold?
Genecentric Therapeutics, Inc. holds 9 US granted patents filed between 2020 and 2025, spanning 6 technology areas.
What is Genecentric Therapeutics, Inc.'s Innovation Score?
Genecentric Therapeutics, Inc. has an Innovation Score of 34.0 out of 100. This composite metric weighs portfolio volume (40%), filing velocity (20%), technology breadth (25%), and claim depth (15%).
What technology areas does Genecentric Therapeutics, Inc. focus on?
Genecentric Therapeutics, Inc.'s top technology area is C12Q (MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS ; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES) with 9 patents. The company has filed patents in 6 CPC subclasses total.
Is Genecentric Therapeutics, Inc.'s patent filing rate increasing or decreasing?
Insufficient historical data is available to calculate a velocity trend for Genecentric Therapeutics, Inc..
What does claim depth mean for Genecentric Therapeutics, Inc.'s patents?
Genecentric Therapeutics, Inc.'s patents average 10.4 claims each. This is relatively simple claim structure, typical for focused inventions.
How is the Genecentric Therapeutics, Inc. patent data sourced?
All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.
How to use this portfolio
Genecentric's 9 grants land it in the top 54% by Innovation Score, but volume alone doesn't tell you where the strength sits.
- Read that count against the largest US assignees before treating it as dominance - Genecentric ranks #28,871 of 50,000. Top 50 holders
- Most of this portfolio concentrates in C12Q - see who else leads that technology area. C12Q leaders
- Check what the four-part Innovation Score actually rewards before comparing it to another company. How the score works
Patent counts and the Innovation Score measure patenting activity, not commercial success or the legal strength of any patent. Many patents are filed defensively. Verify the status of an individual patent against official USPTO records.
Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.